Galderma presents new aesthetic treatment findings in Monaco

Galderma will showcase its latest advancements in aesthetic medicine at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025. The event will feature multiple symposiums, Masterclass sessions, and research presentations aimed at healthcare professionals and patients. A key focus will be new studies on Relfydess®, a neuromodulator that shows effects as soon as day one and maintains high patient satisfaction for six months. In trials, over half of the participants reported visible improvements in their appearance shortly after treatment. Additionally, Galderma will present findings on how weight loss medication affects facial appearance. A significant study involving more than 1,300 individuals found that 93% experienced changes in their face as they lost weight. These findings suggest many people are considering aesthetic treatments to improve their appearance. Symposia at the event will include discussions on medication-driven weight loss effects and expert insights into natural-looking lip treatments. Live demonstrations will also be part of these sessions. Galderma will introduce new information on its facial fillers, including Sculptra and Restylane. Sculptra is recognized as a leading biostimulator, promoting skin regeneration and volume restoration. Restylane is noted for its unique formulation that preserves natural expression while enhancing aesthetic outcomes. Overall, Galderma aims to provide innovative solutions to meet the evolving needs of the aesthetic community, emphasizing patient satisfaction and quality results.